<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="94909"><DrugName>ODM-204</DrugName><DrugSynonyms><Name><Value>ODM-204</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>CYP17 enzyme and androgen receptor inhibitor, Orion corp</Value></Name></DrugSynonyms><CompanyOriginator id="18693">Orion Corp</CompanyOriginator><CompaniesSecondary><Company id="18693">Orion Corp</Company></CompaniesSecondary><CrossReferences><SourceEntity id="18693" type="Company"><TargetEntity id="4295866566" type="organizationId">Orion Oyj</TargetEntity></SourceEntity><SourceEntity id="3246" type="ciIndication"><TargetEntity id="3031" type="siCondition"/></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity></SourceEntity><SourceEntity id="60" type="Action"><TargetEntity id="1746" type="Mechanism">Androgen Receptor Antagonists</TargetEntity></SourceEntity><SourceEntity id="7472" type="Action"><TargetEntity id="376" type="Mechanism">Cytochrome P450 CYP17 A1 (17alpha-Hydroxylase/C17-20 Lyase) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-00135" type="ciTarget"><TargetEntity id="9904399853673" type="siTarget">Androgen receptor</TargetEntity><TargetEntity id="4423" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C1">Phase 1 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="3246">Hormone refractory prostate cancer</Indication></IndicationsSecondary><ActionsPrimary><Action id="60">Androgen receptor antagonist</Action><Action id="7472">Cytochrome P450 17 inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="1545">Anticancer</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2017-08-30T12:48:54.000Z</LastModificationDate><ChangeDateLast>2017-03-09T00:00:00.000Z</ChangeDateLast><AddedDate>2016-10-27T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="30559" linkType="Company"&gt;Orion Corp&lt;/ulink&gt;  was developing ODM-204, a CYP17 enzyme and androgen receptor inhibitor, for the potential oral  treatment of castration-resistant prostate cancer (CRPC). By December 2014, the drug was listed on the website pipeline as being in phase I trial [&lt;ulink linkID="1634010" linkType="Reference"&gt;1634010&lt;/ulink&gt;], [&lt;ulink linkID="1634021" linkType="Reference"&gt;1634021&lt;/ulink&gt;], [&lt;ulink linkID="1629114" linkType="Reference"&gt;1629114&lt;/ulink&gt;].  In March 2015, a phase I/II study was     initiated in patients with metastatic CRPC  [&lt;ulink linkID="1629114" linkType="Reference"&gt;1629114&lt;/ulink&gt;]; however; in October 2016,  the company decided to discontinue trials for treatment of CRPC based on the pharmacokinetic findings of the phase I  trial [&lt;ulink linkID="1866574" linkType="Reference"&gt;1866574&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In January 2015, an open-label, parallel assignment, non-randomized, uncontrolled, multi-center, dose-escalation, first-in-man phase I/II study (&lt;ulink linkID="220427" linkType="Protocol"&gt;NCT02344017&lt;/ulink&gt;; 3116001; DUALIDES) was planned to be initiated in  Finland, the UK and France, to assess the safety and pharmacokinetics of the drug co-administerd orally with &lt;ulink linkID="52065" linkType="Drug"&gt;prednisone&lt;/ulink&gt; in patients (expected n = 75) with metastatic castration-resistant prostate cancer (CRPC). At that time, the study was expected to complete in May 2017 [&lt;ulink linkID="1629114" linkType="Reference"&gt;1629114&lt;/ulink&gt;]. In October 2016, the company decided to discontinue trials for treatment of CRPC based on the pharmacokinetic findings of the phase I  trial [&lt;ulink linkID="1866574" linkType="Reference"&gt;1866574&lt;/ulink&gt;]. In February 2017, clinical data were presented at the 2017 ASCO Genitourinary Cancers Symposium in Orlando, FL. After a single dose of up to 300 mg, the AUC(t) and Cmax values of ODM-204 in plasma increased. A total of three patients had PSA response (&amp;gt;/= 50% reduction from baseline) at week-12. In seven patients (abiraterone and enzalutamide), PSA decreases (median of 47%) were seen [&lt;ulink linkID="1904632" linkType="Reference"&gt;1904632&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By December 2014, the drug was listed on the website pipeline as being in phase I trial [&lt;ulink linkID="1634010" linkType="Reference"&gt;1634010&lt;/ulink&gt;], [&lt;ulink linkID="1634021" linkType="Reference"&gt;1634021&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In January 2016, preclinical data were presented at the ASCO Genitourinary Cancers Symposium in San Francisco, CA. In Vcap xenograft, ODM-204 (60 mg/kg, po) showed better anti-tumor activity than enzulamide, abiraterone or with combination. For 10, 20 and 30 mg/kg of ODM-204 doses, the Cmax was 3.1, 3.7 and 10.2 microM; Tmax was 2.0, 60 and 3.5 h; t1/2 was 4.05, 6.25, and 5.54 h, AUC(0 to t) was 17, 36, and 110 h.microM, respectively, in intact monkeys [&lt;ulink linkID="1727297" linkType="Reference"&gt;1727297&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2015, preclinical data were presented at the ASCO Genitourinary Cancers Symposium in Orlando, FL. ODM-204 (50 mg/kg) decreased tumor growth in a VCaP xenograft model over-expressing AR [&lt;ulink linkID="1637876" linkType="Reference"&gt;1637876&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By December 2014, data had demonstrated that     the drug  was found to bind to   AR with high affinity and inhibited the receptor function by blocking the activity and the nuclear translocation; inhibition of CYP17 enzyme  resulted in  the blockage of  testosterone synthesis  in  males      [&lt;ulink linkID="1634021" linkType="Reference"&gt;1634021&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="18693">Orion Corp</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3246">Hormone refractory prostate cancer</Indication><StatusDate>2016-10-25T00:00:00.000Z</StatusDate><Source id="1866574" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18693">Orion Corp</Company><Country id="LV">Latvia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3246">Hormone refractory prostate cancer</Indication><StatusDate>2016-10-25T00:00:00.000Z</StatusDate><Source id="1866574" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18693">Orion Corp</Company><Country id="FI">Finland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3246">Hormone refractory prostate cancer</Indication><StatusDate>2016-10-25T00:00:00.000Z</StatusDate><Source id="1866574" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="18693">Orion Corp</Company><Country id="FI">Finland</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><StatusDate>2014-12-31T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18693">Orion Corp</Company><Country id="LV">Latvia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><StatusDate>2014-12-29T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18693">Orion Corp</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><StatusDate>2014-12-29T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00135"><Name>Androgen receptor</Name><SwissprotNumbers><Swissprot>O97775</Swissprot><Swissprot>O97776</Swissprot><Swissprot>O97952</Swissprot><Swissprot>O97960</Swissprot><Swissprot>P10275</Swissprot><Swissprot>P15207</Swissprot><Swissprot>P19091</Swissprot><Swissprot>P49699</Swissprot><Swissprot>Q6QT55</Swissprot><Swissprot>Q7T1K4</Swissprot><Swissprot>Q8MIK0</Swissprot><Swissprot>Q9GKL7</Swissprot><Swissprot>Q9TT90</Swissprot></SwissprotNumbers></Target><Target id="PTGT-00578"><Name>Cytochrome P450 17</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></drugRecordOutput>